我們成功的合成出13個直接將benzimidazole與coumarin連結在一起的化合物，且這些化合物皆可由簡單的化學合成方法獲得。藉由核磁共振圖譜、紅外線光譜以及分子模擬的探討，我們發現benzimidazole上NH的氫原子與coumarin上羰基C=O的氧原子之間，其構型在最穩定能量態下沒有觀察到分子內氫鍵的形成，且可觀察到benzimidazole及coumarin此兩平面分子會藉由單鍵的旋轉以63.967°–85.705°的角度扭轉成非共平面結構。此結果在未來討論結構與抑制C型肝炎的活性關係時，可讓我們忽略氫鍵的影響，並有利於讓我們了解所合成出的化合物對於抑制C型肝炎病毒的作用機制。

We successfully obtained thirteen hinged benzimidazole–coumarin hybrids; these compounds were obtained by simple chemical synthesis. By studies of the spectra of nuclear magnetic resonance and infrared spectroscopy as well as the outcomes of molecular modeling, we conclude that the conformation with the thermodynamically most stable form did not contain intramolecular hydrogen bondings between the NH proton in benzimidazole and the carbonyl group in coumarin. The angle between benzimidazole and coumarin planes were 63.967°–85.705°. In the future, we will discuss the structure–activity relationship of anti-HCV, the results shall help us to understand the mechanism that the compounds for the inhibition of hepatitis C virus.

1. Simmonds, P. Genetic diversity and evolution of hepatitis C virus – 15 years on. J. Gen. Virol. 2004, 85, 3173–3188.
2. Hoofnagle, J. H. Course and outcome of hepatitis C. Hepatology 2002, 36, S21–S29.
3. Choo, Q.-L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989, 244, 359–362.
4. Simmonds, P.; Bukh, J.; Combet, C.; Deléage, G.; Enomoto, N.; Feinstone, S,; Halfon, P,; Inchauspé, G.; Kuiken, C.; Maertens, G.; Mizokami, M.; Murphy, D. G.; Okamoto, H.; Pawlotsky, J.-M.; Penin, F.; Sablon, E.; Shin-I, T.; Stuyver, L. J.; Thiel, H.-J.; Viazov, S.; Weiner, A. J.; Widell, A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42, 962–973.
5. Pawlotsky, J.-M.; Gish, R. G. Future therapies for hepatitis C. Antivir. Ther. 2006, 11, 397–408.
6. Moradpour, D.; Penin, F.; Rice, C. M. Replication of hepatitis C virus. Nature Rev. Microbiol. 2007, 5, 453–463.
7. Lauer, G. M.; Walker, B. D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345, 41–52.
8. Roingeard, P.; Hourioux, C. Hepatitis C virus core protein, lipid droplets and steatosis. J. Viral Hepat. 2008, 15, 157–164.
9. De Francesco, R.; Tomei, L.; Altamura, S.; Summa, V.; Migliaccio, G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res. 2003, 58, 1–16.
10. Di Bisceglie, A. M.; Hoofnagle, J. H. Optimal therapy of hepatitis C. Hepatology 2002, 36, S121–S127.
11. Zein, N. N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J. Hepatol. 2005, 42, 315–322.
12. Bretner, M. Existing and future therapeutic options for hepatitis C virus infection. Acta Biochim. Pol. 2005, 52, 57–70.
13. Manns, M. P.; Foster, G. R.; Rockstroh, J. K.; Zeuzem, S.; Zoulim, F.; Houghton, M. The way forward in HCV treatment – finding the right path. Nature Rev. Drug Discov. 2007, 6, 991–1000.
14. Hirashima, S.; Suzuki, T.; Ishida, T.; Noji, S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda, S.; Hashimoto, H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure–activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem. 2006, 49, 4721–4736.
15. Andrzejewska, M.; Y´epez-Mulia, L.; Cedillo-Rivera, R.; Tapia, A.; Vilpo, L.; Vilpo, J.; Kazimierczuk, Z. Synthesis, antiprotozoal and anticancer activity of substituted 2-trifluoromethyl- and 2-pentafluoroethylbenzimidazoles. Eur. J. Med. Chem. 2002, 37, 973–978.
16. Gümüş, F.; Algül, Ö.; Eren, G.; Eroğlu, H.; Diril, N.; Gür, S.; Özkul. A. Synthesis, cytotoxic activity on MCF-7 cell line and mutagenic activity of platinum(II) complexes with 2-substituted benzimidazole ligands. Eur. J. Med. Chem. 2003, 38, 473–480.
17. Ito, C.; Itoigawa, M.; Mishina, Y.; Filho, V. C.; Enjo, F.; Tokuda, H.; Nishino, H.; Furukawa, H. Chemical constituents of Calophyllum brasiliense. 2. structure of three new coumarins and cancer chemopreventive activity of 4-substituted coumarins. J. Nat. Prod. 2003, 66, 368–371.
18. Chilin, A.; Battistutta, R.; Bortolato, A.; Cozza, G.; Zanatta, S.; Poletto, G.; Mazzorana, M.; Zagotto, G.; Uriarte, E.; Guiotto, A.; Pinna, L. A.; Meggio, F.; Moro, S. Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure–activity relationships. J. Med. Chem. 2008, 51, 752–759.
19. Robert, S.; Bertolla, C.; Masereel, B.; Dogné, J.-M.; Pochet, L. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J. Med. Chem. 2008, 51, 3077–3080.
20. Kamal, A.; Ramulu, P.; Srinivas, O.; Ramesh, G.; Kumar, P. P. Synthesis of C8-linked pyrrolo[2,1-c][1,4]benzodiazepinebenzimidazole conjugates with remarkable DNA-binding affinity. Bioorg. Med. Chem. Lett. 2004, 14, 4791–4794.
21. Chauhan, P. M. S.; Martins, C. J. A.; Horwell, D. C. Synthesis of novel heterocycles as anticancer agents. Bioorg. Med. Chem. 2005, 13, 3513–3518.
22. Demirayak, S.; Mohsen, U. A.; Karaburun, A. C. Synthesis and anticancer and anti-HIV testing of some pyrazino[1 2-a]benzimidazole derivatives. Eur. J. Med. Chem. 2002, 37, 255–260.
23. Garuti, L.; Roberti, M.; Malagoli, M.; Rossi, T.; Castelli, M. Synthesis and antiproliferative activity of some benzimidazole-4 7-dione derivatives. Bioorg. Med. Chem. Lett. 2000, 10, 2193–2195.
24. Lukevics, E.; Arsenyan, P.; Shestakova, I.; Domracheva, I.; Nesterova, A.; Pudova, O. Synthesis and antitumour activity of trimethylsilylpropyl substituted benzimidazoles. Eur. J. Med. Chem. 2001, 36, 507–515.
25. Handratta, V. D.; Vasaitis, T. S.; Njar, V. C. O.; Gediya, L. K.; Kataria, R.; Chopra, P., Jr.; Farquhar, R.; Guo, Z.; Qiu, Y.; Brodie, A. M. H. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 2005, 48, 2972–2984.
26. Curini, M.; Epifano, F.; Maltese, F.; Marcotullio, M.C.; Gonzales, S.P.; Rodriguez, J.C. Synthesis of collinin, an antiviral coumarin. Aust. J. Chem. 2003, 56, 59–60.
27. Bretner, M.; Baier, A.; Kopanska, K.; Najda, A.; Schoof, A.; Reinholz, M.; Lipniacki, A.; Piasek, A.; Kulikowsi, T.; Borowski, P. Synthesis and biological activity of 1H-benzotriazole and 1Hbenzimidazole analoguessinhibitors of the NTPase/helicase of HCV and of some related Flaviviridae. AntiViral Chem. Chemother. 2005, 16, 315–326.
28. Komazin, G.; Ptak, R. G.; Emmer, B. T.; Townsend, L. B.; Drach, J. C. Resistance of human cytomegalovirus to D- and L-Ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs. Nucleosides, Nucleotides Nucleic Acids 2003, 22, 1725–1727.
29. Reddy, P. N.; Reddy, Y. T.; Rao, M. K.; Rajitha, B. Synthesis and anticancer activity of novel benzimidazole chromenes, thiadiazolyl chromenes under microwave irradiation conditions. Heterocycl. Commun. 2003, 9, 647–652.
30. Lee, S.; Sivakumar, K.; Shin, W.-S.; Xie, F.; Wang, Q. Synthesis and anti-angiogenesis activity of coumarin derivatives. Bioorg. Med. Chem. Lett. 2006, 16, 4596–4599.
31. Beaulieu, P. L.; Bousquet, Y.; Gauthier, J.; Gillard, J.; Marquis, M.; McKercher, G.; Pellerein, C.; Valois, S.; Kukolj, G. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 Cells. J. Med. Chem. 2004, 47, 6884–6892.
32. Beaulieu, P. L.; Bös, M.; Bousquet, Y.; DeRoy, P.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; McKercher, G.; Poupart, M.-A.; Valois, S.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett. 2004, 14, 967–971.
33. Ishida, T.; Suzuki, T.; Hirashima, S.; Mizutani, K.; Yoshida, A.; Ando, I.; Ikeda, S.; Adachi, T.; Hashimoto, H. Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy) phenyl]-benzimidazole. Bioorg. Med. Chem. Lett. 2006, 16, 1859–1863.
34. Hwu, J. R.; Singha, R.; Hong, S. C.; Chang, Y. H.; Das, A. R.; Vliegen, I.; DeClercq, E.; Neyts, J. Synthesis of new benzimidazole–coumarin conjugates as anti-hepatitis C virus agents. Antiviral Res. 2008, 77, 157–162.
35. Neyts, J.; Clercq, E. D.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S. K.; Hong, S. C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J. R. Structure–activity relationship of new anti-hepatitis C virus agents: heterobicycle–coumarin conjugates. J. Med. Chem. 2009, 52, 1486–1490.
36. Aldrich Chemical Co. http://www.sigmaaldrich.com/taiwan.html
37. Nakanishi, K.; Solomon, P. H. Infrared Absorption Spectroscopy, 2nd ed.; Holden-Day: Oakland, CA, 1977; p 38.
38. Krishnakumar, V.; Seshadri, S.; Muthunatasen, S. Analysis of vibrational spectra of 5,6-dimethyl benzimidazole based on density functional theory calculations. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2007, 68, 811–816.
39. (a) http://accelrys.com/ (b) http://www.molsci.com.tw/index.html
40. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry. J. Med. Chem. 2010, 53, 2601–2611.